

IN THE CLAIMS

Kindly add the following claims:

¹¹
--~~25~~. The method of Claim 1, which further includes the administration of at least one chemotherapeutic agent.

¹²
~~26~~. The method of Claim ¹¹~~25~~, wherein the chemotherapeutic agent is administered after the administration of said immunologically active chimeric anti-CD20 antibody.

¹³
~~27~~. The method of Claim ¹¹~~25~~, wherein the chemotherapeutic agent is administered prior to the administration of said immunologically active chimeric anti-CD20 antibody.

¹⁴
~~28~~. The method of Claim ¹¹~~25~~, wherein the chemotherapeutic agents are selected from the group consisting of cyclophosphamide doxorubicin, vincristine and prednisone.--

REMARKS

Entry of the foregoing amendments, reconsideration and reexamination of the subject application, as amended, pursuant to and consistent with 37 C.F.R. §1.112, and in light of the remarks which follow, are respectfully requested.

By the present amendment, Claims 25-28 have been added which are directed to additional embodiments of the invention. These new claims find support in the application at page 61, line 22 to